Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 1-11373 Cardinal Health, Inc. (Exact name of registrant as specified in its charter) (State or other j ...

1 © 2025 Cardinal Health. All Rights Reserved. • Q1 FY26 Earnings Cautions Concerning Forward-Looking Statements This presentation contains forward-looking statements addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. These statements may be identified by words such as "expect," "anticipate," "intend," "plan," "believe," "will," "should," "could," "would," "project," "continue," "likely," and similar expressions, and include statements refl ...

Drug distributor Cardinal Health raised its annual adjusted profit forecast on Thursday after beating estimates for first-quarter profit on strong demand for costly specialty medicines and branded dru... ...

Exhibit 99.1 FOR IMMEDIATE RELEASE Cardinal Health Reports First Quarter Fiscal Year 2026 Results and Raises Outlook DUBLIN, Ohio, October 30, 2025 - Cardinal Health (NYSE: CAH) today reported first quarter fiscal year 2026 revenues of $64 billion, an increase of 22% from the first quarter of fiscal year 2025. First quarter GAAP operating earnings increased 18% to $668 million and GAAP diluted earnings per share (EPS) increased 11% to $1.88. First quarter non-GAAP operating earnings increased 37% to $857 mi ...

| Q1 FY26 Q1 FY25 Y/Y | | | --- | --- | | Revenue $64.0 billion $52.3 billion 22Â % | | | Operating earnings $668 million $568 million 18Â % | | | Non-GAAP operating earnings $857 million $625 million 37Â % | | | Net earnings attributable to Cardinal Health, Inc. $450 million $416 million 8Â % | | | Non-GAAP net earnings attributable to Cardinal Health, Inc. $611 million $460 million 33Â % | | | Effective Tax Rate 24.1Â % 23.0Â % | | | Non-GAAP Effective Tax Rate 21.9Â % 23.0Â % | | | Diluted EPS attributab ...

Key Takeaways CAH's Q1 revenues are projected at $59.05B, up 13% year over year, with EPS of $2.21.CAH's Pharmaceutical and Specialty Solutions unit likely drove gains from biosimilars and GLP-1 therapies.Tariff costs, higher SG&A, and acquisition expenses may have pressured CAH's margins despite segmental growth.Cardinal Health, Inc. (CAH) is scheduled to report first-quarter fiscal 2026 results on Oct. 30, before market open.In the last reported quarter, the company’s adjusted earnings per share (EPS) of ...

核心观点 - Cardinal Health公司的股票相对强度评级从70提升至74，显示出改善的价格表现 [1] 相对强度评级变化 - Cardinal Health股票的相对强度评级进入新的百分位，评级得分为74 [1] - 相对强度评级使用1（最差）到99（最佳）的评分体系，衡量股票过去52周的价格表现 [1] - 相关新闻标题多次提及Cardinal Health的相对强度评级提升，例如从71跳升至81 [3]

公司业务概览 - 公司是一家主要的药品和医疗产品分销商，业务涵盖品牌药、仿制药、专业药品、非处方医疗产品和消费品 [2] - 公司还生产并销售自有品牌的医疗和外科产品，包括手套、手术服和液体管理产品 [3] - 公司运营一个大型放射性药房网络，并提供医院药房支持、家庭护理解决方案和物流管理等一系列服务 [3] 财务状况与股息 - 公司在2025财年产生了25亿美元的调整后自由现金流 [4] - 公司预计2026财年的调整后自由现金流将在27.5亿美元至32.5亿美元之间 [4] - 得益于健康的现金流，公司已连续39年增加股息支付 [4] - 截至10月9日，公司季度股息为每股0.5107美元，股息收益率为1.30% [4]

公司概况与近期事件 - 公司为医疗保健服务与产品公司 市值达366亿美元 业务涵盖医药分销、产品制造与咨询、药物输送系统开发及零售药房特许经营等 [1] - 公司预计于2026财年第一季度（10月30日周四）开盘前公布业绩 [1] 财务业绩预期 - 分析师预计第一季度稀释后每股收益为2.21美元 较上年同期的1.88美元增长17.6% [2] - 公司过去四个季度的每股收益均超出华尔街预期 [2] - 2026财年全年每股收益预期为9.45美元 较2025财年的8.24美元增长14.7% [3] - 2027财年每股收益预计将同比增长12% 达到10.58美元 [3] 股价表现与市场对比 - 过去52周公司股价上涨39% 但显著跑输同期上涨14.7%的标普500指数($SPX) [4] - 同期表现亦不及医疗保健精选行业SPDR基金(XLV) 该基金下跌7.8% [4] - 8月12日公司公布第四季度业绩后股价下跌7.2% 尽管调整后每股收益增长13%至2.08美元并超预期 但602亿美元的收入略低于预期 可能削弱了投资者信心 [5] 分析师观点与目标价 - 分析师整体看法为看涨 给予“强力买入”评级 覆盖该股的15位分析师中 11位建议“强力买入” 4位建议“持有” [6] - 平均目标价为179.80美元 暗示较当前水平有15.5%的潜在上涨空间 [6]

公司业务扩张 - 公司计划在印第安纳州印第安纳波利斯建设一个新的旗舰级前沿配送中心，以扩展和现代化其全国药品分销网络 [3] - 新设施将采用先进的自动化和尖端技术，支持每日分发超过70,000种药品和特种产品 [3] - 这是公司自2024年以来宣布的第二个药品分销中心，预计将于2027年秋季全面投入运营，并为该州创造超过100个新工作岗位 [4] 公司财务表现 - 公司因其财务一致性而突出，已连续39年增加股息 [5] - 截至10月14日，公司提供每股0.5107美元的季度股息，股息收益率为1.33% [5] 行业地位与投资属性 - 公司被列为当前值得购买的11只防御性医疗保健股息股票之一 [1] - 公司是防御性医疗保健行业中最佳的股息股票之一 [2]